Literature DB >> 187332

Mechanism of action of 2-amino-1,3,4-thiadiazole (NSC 4728).

J A Nelson, L M Rose, L L Bennett.   

Abstract

The synthesis and isolation of two derivatives of 2-amino-1,3,4-thialdiazole(aminothiadiazole) are described. The derivatives are a nicotinamide adenine dinucleotide (NAD) analog prepared by an exchange reaction with NAD in the presence of nicotineamide adenine dinucleotide glycohydrolase and a presumed aminothiadiazole mononucleotide prepared by treatment of the NAD analog with nucleotide pyrophosphatase. Both derivatives are potent inhibitors of inosine 5'-phosphate (IMP) dehydrogenase obtained from leukemia L1210 cells. The NAD analog is a pseudoir-reversible inhibitor of the enzyme, noncompetitive with either IMP or NAD. The aminothiadiazole mononucleotide has a K1 of about 0.1 muM, is competitive with IMP, and is uncompetitive with NAD: the inhibition appears to be reversible by Ackermann-Potter analysis. A metabolite of [5-14C]aminothiadiazole is formed in L1210 cells in vivo to a level of 0.3 nmole/10(9) cells. Retention volume of the metabolite on a high-pressure liquid chromatography system is the same as that of the aminothiadiazole mononucleotide prepared as described above. These results suggest that IMP dehydrogenase is the site of action for aminothiadiazole metabolites as was indicated by earlier observations. There is no evidence that the NAD analog is formed in vivo. Nicotinamide prevented formation of the mononucleotide in vivo. Therefore, since formation and cleavage of the NAD analog apparently are not the route to the thiadiazole nucleotide, some other pathway for the metabolism of nicotinamide may be involved such as the action of a phosphoribosyltransferase or the sequential action of a nucleoside phosphorylase and a nucleoside kinase.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 187332

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  9 in total

1.  Evaluation of the anti-influenza virus activities of 1,3,4-thiadiazol-2-ylcyanamide (LY217896) and its sodium salt.

Authors:  J M Colacino; D C DeLong; J R Nelson; W A Spitzer; J Tang; F Victor; C Y Wu
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 2.  Heberden oration 1979: human aberrations of purine metabolism and their significance for rheumatology.

Authors:  J E Seegmiller
Journal:  Ann Rheum Dis       Date:  1980-04       Impact factor: 19.103

3.  Adenosine kinase initiates the major route of ribavirin activation in a cultured human cell line.

Authors:  R C Willis; D A Carson; J E Seegmiller
Journal:  Proc Natl Acad Sci U S A       Date:  1978-07       Impact factor: 11.205

4.  Contributions of Lesch-Nyhan syndrome to the understanding of purine metabolism.

Authors:  J E Seegmiller
Journal:  J Inherit Metab Dis       Date:  1989       Impact factor: 4.982

5.  Inosine-5'-monophosphate dehydrogenase is a rate-determining factor for p53-dependent growth regulation.

Authors:  Y Liu; S A Bohn; J L Sherley
Journal:  Mol Biol Cell       Date:  1998-01       Impact factor: 4.138

6.  Phase II trials of 5-day vinblastine infusion (NSC 49842), L-alanosine (NSC 153353), acivicin (NSC 163501), and aminothiadiazole (NSC 4728) in patients with recurrent or metastatic renal cell carcinoma.

Authors:  P J Elson; L K Kvols; S E Vogl; D J Glover; R G Hahn; D L Trump; P P Carbone; J D Earle; T E Davis
Journal:  Invest New Drugs       Date:  1988-06       Impact factor: 3.850

Review 7.  Aminothiadiazoles.

Authors:  D L Hill
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

8.  Clinical and clinical pharmacologic studies of 2-amino-1,3,4-thiadiazole (A-TDA:NSC 4728).

Authors:  J A Stewart; C C Ackerly; C F Myers; R A Newman; I H Krakoff
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

Review 9.  Thiadiazole derivatives as anticancer agents.

Authors:  Monika Szeliga
Journal:  Pharmacol Rep       Date:  2020-09-03       Impact factor: 3.024

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.